Healius Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

HealiusDie Umsatzerlöse des Unternehmens werden voraussichtlich um 4.8% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 85.2% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 104.4% pro Jahr wachsen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 2.3% betragen.

Wichtige Informationen

85.2%

Wachstumsrate der Gewinne

104.4%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	25.1%
Wachstumsrate der Einnahmen	-4.8%
Zukünftige Eigenkapitalrendite	2.3%
Analystenabdeckung	Good
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

ASX:HLS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2027	1,465	23	202	232	8
6/30/2026	1,398	13	144	215	9
6/30/2025	1,677	195	249	297	7
6/30/2024	1,746	-636	203	267	N/A
12/31/2023	1,692	-984	217	284	N/A
9/30/2023	1,699	-682	237	309	N/A
6/30/2023	1,707	-380	257	333	N/A
12/31/2022	1,839	35	313	407	N/A
9/30/2022	2,064	164	403	497	N/A
6/30/2022	2,289	292	493	587	N/A
12/31/2021	2,292	226	549	624	N/A
9/30/2021	2,103	146	506	575	N/A
6/30/2021	1,914	66	464	526	N/A
3/31/2021	1,802	75	460	512	N/A
12/31/2020	1,690	83	456	497	N/A
9/30/2020	1,630	83	395	452	N/A
6/30/2020	1,570	83	333	407	N/A
12/31/2019	1,502	110	99	233	N/A
9/30/2019	1,534	83	49	180	N/A
6/30/2019	1,566	57	-2	128	N/A
3/31/2019	1,785	29	23	140	N/A
12/31/2018	1,752	2	48	153	N/A
9/30/2018	1,728	3	74	177	N/A
6/30/2018	1,705	4	99	202	N/A
3/31/2018	1,694	-256	N/A	215	N/A
12/31/2017	1,683	-516	N/A	227	N/A
9/30/2017	1,671	-516	N/A	220	N/A
6/30/2017	1,659	-517	N/A	212	N/A
3/31/2017	1,648	-260	N/A	219	N/A
12/31/2016	1,637	-3	N/A	227	N/A
9/30/2016	1,639	18	N/A	256	N/A
6/30/2016	1,642	38	N/A	285	N/A
12/31/2015	1,595	126	N/A	270	N/A
9/30/2015	1,587	121	N/A	255	N/A
6/30/2015	1,580	117	N/A	239	N/A
3/31/2015	1,596	127	N/A	256	N/A
12/31/2014	1,572	118	N/A	271	N/A
9/30/2014	1,548	116	N/A	266	N/A
6/30/2014	1,524	115	N/A	261	N/A
3/31/2014	1,501	134	N/A	256	N/A
12/31/2013	1,478	131	N/A	243	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HLS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).

Ertrag vs. Markt: HLS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: HLS wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: HLSDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-4.8% pro Jahr).

Hohe Wachstumseinnahmen: HLSDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-4.8% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: HLSDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (2.3%).

Healius Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 14% to AU$1.77

Price target increased by 8.4% to AU$1.68

Price target increased by 7.5% to AU$1.51

Consensus EPS estimates fall by 37%

Consensus EPS estimates fall by 37%

Consensus EPS estimates increase by 34%

Recent updates

Price target increased by 14% to AU$1.77

Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.

Price target increased by 8.4% to AU$1.68

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Healius Limited, Annual General Meeting, Nov 15, 2024

Price target increased by 7.5% to AU$1.51

Full year 2024 earnings: Revenues exceed analyst expectations

TPG Capital, PEP Reportedly Still Competing for Healius Lumus Imaging

Final Bids Reportedly Expected for Healius

Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024

Macquarie Unit Reportedly in Healius Race

Healius Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Sonic in the Running for Healius Imaging Business

Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings: Revenues miss analyst expectations

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 37%

Consensus EPS estimates fall by 37%

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

Consensus EPS estimates increase by 34%

Consensus EPS estimates increase by 36%

Consensus EPS estimates increase by 22%

High number of new directors

Consensus EPS estimates increase by 18%

Is Healius Limited (ASX:HLS) Trading At A 50% Discount?

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Consensus EPS estimates increase by 17%

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Consensus EPS estimates fall by 21%

At AU$3.07, Is It Time To Put Healius Limited (ASX:HLS) On Your Watch List?

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Consensus forecasts updated

Price target decreased to AU$3.23

Consensus EPS estimates fall by 13%

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

Here's Why Healius (ASX:HLS) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 27%

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Is Now An Opportune Moment To Examine Healius Limited (ASX:HLS)?

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock

MD, CEO & Director exercised options to buy AU$2.2m worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Healius Limited Announces Fully Franked Ordinary Paid Dividend for the Six Months Ended June 30, 2022, Payable on September 21, 2022

Healius Limited, Annual General Meeting, Oct 20, 2022

Are Investors Undervaluing Healius Limited (ASX:HLS) By 48%?

Healius Reportedly Launches Day Surgery Sale Process

Price target decreased to AU$4.30

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Consensus EPS estimates fall by 13%

Healius Limited to Report Fiscal Year 2022 Results on Aug 31, 2022

Why Healius Limited (ASX:HLS) Could Be Worth Watching